Antibody Research

Antibody Research

PIM proteins are emerging as important therapeutic targets in various diseases, including cancer. Our groundbreaking research aims to inhibit PIM activity, offering new strategies for combating cancer, covid, and other PIM-associated disorders.

Research
  • Licensing Status

    Our Antibody Research is ongoing

Project Details

Our research in next-generation adjuvants and PIM inhibition represents our commitment to a future where diseases are managed more effectively and lives are enhanced.

Patents